Over the past month, the U.

S Europe and countries like Israel have approved at least one covert 19 vaccine on, although the contenders got off to a similar start.

Ah, clear winner has already emerged.

Israel has inoculated 15% of its population, and that's down to three factors.

The main reason isn't paid a premium to get early doses off the Pfizer biotech vaccine.

It's also gone for a centralized approach to getting vaccines to its people.

This means that it uses around 400 vaccination centers.

But most crucially, it seems to have a more willing public.

It already had a vaccination registry, which makes it easier for the government to contact people to let them know when they need a vaccine.

On a follow up dose, the UK was the first out of the blocks on.

Although it's managed to vaccinate over a million people, challenges lie ahead.

It needs to recruit staff and actually build the vaccination centers themselves.

Without that, they are now using a decentralized approach hospitals and doctors offices to administer vaccines.

But the problem is, the National Health Service is already overwhelmed.

Over 1000 people are dying a day in the UK, which makes it more difficult to administer these vaccines in the hospitals.

But France is the clear lag art.

At the beginning of this month, it had only inoculated around 500 of its citizens, and that may seem counterintuitive.

France boasts one of the best health care systems in the world, but it also appears to have a very fearful public.

In a recent poll, 60% of its citizens said that they would not take a covert 19 vaccine.

And although that number has fallen to around 40% in recent days, that's still a lot of people that need to be convinced to take the vaccine.

Investors seemed to have already clocked this.

The value of Israel's top 125 companies has gone up by around 6% since the start of December.

Britain's Footsie 100 index has gone up by a similar level, but France's top 40 companies has only gone up by around 2%.